Introduction
Clinical guidelines are considered crucial for improving the quality of antibiotic prescribing, both to ensure improved outcome of empirical therapy and to reduce inappropriate antibiotic use in the relentless battle against antibiotic resistance.
Whilst much effort has been directed towards the development of guidelines for antibiotic therapy for specific clinical conditions, 1, 2 there is little information available on the structure and content of antibiotic policies and formularies, particularly at a European level. In 2000, an expert group reported that little was known about which stewardship measures were employed in Europe and which were optimal. 3 Various initiatives have since been implemented throughout Europe to support the prudent use of antimicrobials, including the Antibiotic Stewardship International project, supported by the EU Commission. 4 This collaborative project aims to provide tools for implementing antibiotic stewardship programmes across 40 European hospitals and will develop valid process and outcome measures as quality indicators of antibiotic use. These measures will be based on published recommendations, systematic reviews, clinical guidelines and other European initiatives on antibiotic consumption [e.g. the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Study Group on Antibiotic Policies (ESGAP)]. However, there is a paucity of descriptive data on antibiotic policies and practice in Europe and there are no baseline data against which current initiatives can be judged. This study was performed within a wider Concerted Action project funded by the Directorate General (DG) Research of the European Commission (Study title: Antibiotic Resistance Prevention and Control, ARPAC: QLK2-CT-2001-00915). 5 The ARPAC study undertook a Europe-wide survey to investigate the structure, design and content of written hospital antibiotic policies and formularies and to explore whether variation existed across Europe. A subset of key antibiotic stewardship indicators were analysed by antimicrobial usage to investigate the relationship between quality indicators and antibiotic consumption.
Methods

Study population
Methods for the ARPAC study have been described in full elsewhere. 5 -10 In brief, this was an observational cross-sectional study funded from January 2002 to June 2005. All members of ESCMID were invited to participate in the ARPAC study and asked to provide hospital antibiotic policy and consumption data relating to 2001. Of 293 hospitals expressing an interest in participating, 263 were eligible to contribute data.
Questionnaire survey
In 2003, a detailed postal questionnaire was developed in English by the ARPAC Steering Group and was piloted twice on a subsample of 10 acute care hospitals in different countries. Questions from previously completed studies were used to inform item development.
11,12
The questionnaire requested data on antibiotic prescribing and included sections on: committees, formularies, policies, antibiotic availability and policies addressing empirical therapy and prophylaxis. The questionnaire was to be completed by an appropriate professional (microbiologist, infectious diseases physician or pharmacist). Definitions were provided within the questionnaire. 'Formulary' was defined as a list of antibiotics routinely stocked in the hospital; 'antibiotic policy' as provision of guidelines for antibiotic prescribing; and 'restricted antibiotic' was defined as a formulary antibiotic that could only be prescribed with additional authorization. Key indicators of antibiotic 'stewardship' were short listed by the Steering Group and, after discussion, the listing was reduced to six factors. These were agreed a priori: the hospital had (i) an antibiotic committee; (ii) a written antibiotic policy; (iii) a written antibiotic formulary; (iv) a formulary which included a restricted antibiotic list; (v) a drugs and therapeutics committee (DTC); and (vi) a strategic management goal of improving prescribing.
Antibiotic use data
Hospital antibiotic use data, measured in defined daily doses per 100 occupied bed-days (DDD/100 BD), were collated using a preformatted Excel spreadsheet.
13 Antibacterial agents were categorized using the Anatomical Therapeutic Chemical (ATC) classification index with 2005 WHO DDDs.
14 Data were collected for all antibacterial agents for systemic use (ATC Group J01) and other classes for in-hospital use only. A subset of antibiotics was selected a priori for analysis and has been presented previously: 8 total agents (J01); total agents minus glycopeptides (J01XA); cephalosporins (J01DA); third-generation cephalosporins (J01DD); fluoroquinolones (J01MA); macrolides (J01FA); and aminoglycosides (J01G).
Statistical analysis
Data were entered into Microsoft Access 2000, with an independent double-data entry validation check conducted on a 10% sample. Statistical analysis was conducted using SPSS for Windows (version 16.0); data were analysed by five previously described European regions. 5 -9 Descriptive analyses were conducted to identify associations between key stewardship variables and geographic location, hospital size, teaching status and case mix variables [ presence and size of adult and/or paediatric intensive care unit (ICU), number of long-stay beds expressed as a proportion of total beds]. Data were analysed by European region using a modified version of a standard European reference system, with UK hospitals categorized as Western rather than Northern Europe. Given the potential for multiple statistical testing, only six stewardship variables were selected and P values of ,0.01 were considered statistically significant. Distributions were analysed using medians [interquartile range (IQR)] and non-parametric tests were used (Mann -Whitney U-test/Kruskal-Wallis test). Median (IQR) antibiotic consumption values at the hospital level were analysed by key indicators of antibiotic stewardship.
Results
Antibiotic stewardship data were received from 170 (65%) of 263 ARPAC hospitals from 32 European countries; 10 antibiotic consumption data were provided by 139 hospitals from 30 countries, 9 and 124 hospitals provided both data sets. Of the 170 hospitals providing antibiotic policy data, 130 (76%) had teaching status, 159 (94%) had an ICU and median hospital size was 669 beds (IQR 408, 1022 
Key stewardship variables by European region
Almost half of all European hospitals surveyed reported not having an antibiotic committee (n¼ 77; 45%) (Table 1) , although most hospitals had a DTC (86%). There was significant variation across Europe, with .98% of hospitals from Northern and Western Europe having a DTC compared with 68% -69% of hospitals in Southern and South-Eastern Europe (P, 0.001). Seventeen (10%) teaching hospitals had neither an antibiotic committee nor a DTC; of these, 13 were from Southern or South-Eastern Europe (data not shown). There were differences in the distribution of written antibiotic policies and antibiotic formularies, with hospitals in Northern and Western Europe being more likely to have policies compared with those in Southern and South-Eastern regions (P,0.001). Twenty-four hospitals (14%), all of which had teaching status, had neither an antibiotic policy nor a formulary; of these, 16 were from Southern or South-Eastern Europe.
Hospitals from Northern Europe were less likely to include restrictions on antibiotics within the formulary compared with other regions (P ¼0.02). Forty-one hospitals (24%) had no restricted list of antibiotics; of these hospitals, 11 were from Northern and 15 from Western Europe. A higher proportion of hospitals from Central-East Europe reported that improved prescribing was a strategic management goal, although differences were not statistically significant. Responses to antibiotic stewardship questions were compared by case mix. Smaller hospitals (,500 beds) were less likely to have an antibiotic committee (P ¼ 0.01) or a DTC (P ¼ 0.02) compared with larger hospitals.
Thirty-seven (22%) of the responding European hospitals reported they had neither an antibiotic committee nor a written antibiotic policy. Of these, half were from Southern or South-Eastern Europe. Of the 37 hospitals, 12 also reported having no written antibiotic formulary or DTC. Table 2 presents data on membership of committees and regularity of meetings. Infection control personnel were less likely to be involved with DTCs compared with pharmacy and other infectious diseases/microbiology staff. Most 'other' personnel attending committee meetings included other medical staff and, occasionally, hospital management representatives. Local DTCs (38%) or local antibiotic committees (34%) were mostly responsible for the content and revision of antibiotic formularies.
Structure and content of written antibiotic policies
For the 97 hospitals with a written antibiotic policy, 63 (65%) reported that the policy fitted into a doctor's white coat pocket and 51 (53%) contained an index section. Policy length ranged from 2 to 275 pages (mean 46 pages) but only 22 (23%) hospitals published the policy document on the hospital intranet. Most policies emphasized the risks of antimicrobial resistance but fewer referred to local resistance patterns (Table 3) . Only 14% of hospital policies included a programme for cycling of antibiotics although 70% did recommend switching from parenteral to oral therapy.
With regards to therapy, most policies recommended empirical therapy for specific indications (81%; Table 4 ). Policy documents frequently included recommendations on individual drugs, first choice of antibiotics, alternative choices, dosage, duration, route of administration and data on specific causative microorganisms (Table 4) . However, they were less likely to contain information on drug class, side effects, costs and advice on revision of empirical therapy.
Surgical prophylaxis
Regarding prophylaxis, 81 (84%) hospital policies made recommendations for surgical prophylaxis and 78 (80%) listed procedures where prophylaxis was indicated. Specific recommendations included: first choice of antibiotics (82%), alternative antibiotic choices (69%), timing of administration (81%), importance of administration within 2 h of surgery 53 (98) 27 (68) 9 (69) 38 (88) 146 (86) 1 (1) ,0.001
Hospital had a written antibiotic formulary 16 (84) 51 (94) 23 (59) 5 (42) 36 (84) 131 (77) 3 (2) ,0.001
Written formulary had a restricted list of antibiotics 7 (39) 36 (71) 21 (78) 7 (78) 32 (82) 103 (61) 26 (15) 0.02
Hospital had a written antibiotic policy 15 (79) 39 (72) 18 (46) 3 (25) 22 (54) 97 (57) 5 (3) 0.003
Hospital had an antibiotic committee 14 (74) 30 (57) 17 (45) 4 (31) 24 (56) 89 (52) 4 (2) 0.12
Improving prescribing was a strategic management goal 8 (44) 32 (59) 17 (46) 5 (46) 25 (61) 87 (51) 9 (5) 0.50
Hospital had neither an antibiotic committee nor an antibiotic policy 2 (5) 7 (19) 13 (35) 6 (16) 9 (24) 37 (22) 9 (5) 0.02 CE, Central-East; SE, South-Eastern.
(75%), single-dose prophylaxis (74%), restriction of prophylaxis to within 24 h (71%), dosage (78%), repeat dosing (71%) and route of administration (80%). Information and advice on microorganisms covered by the antibiotic listed (37%), side effects (13%) and costs of products (24%) were less likely to be included in the surgical prophylaxis section.
Annual antibiotic consumption by policy Table 6 .
Discussion
The aim of this study was to investigate the structure, design and content of antibiotic policies within 170 hospitals in Europe and to explore relationships between key stewardship factors and antibiotic consumption data. To our knowledge, although conducted in 2003, this is the largest cross-sectional study investigating variation in hospital antibiotic stewardship across European regions. Our findings provide a useful baseline of hospital antibiotic policies and practice; newer stewardship initiatives can use these data as a basis for benchmarking and comparison.
Our finding that only 57% of European hospitals surveyed had a written antibiotic policy is no improvement on similar findings from the UK published over a decade ago. 12 We found that key stewardship factors varied across European regions, with marked differences between Northern and Western Europe compared with Southern and South-Eastern regions, where hospitals were less likely to use antibiotic policies or convene antibiotic-related committees. Hospitals in countries from Central-East Europe had similar policies and practices to those observed in the North-West, although not quite to the same degree. It was disconcerting to find that, of participating hospitals, one-fifth of major teaching hospitals in Europe reported having neither an antibiotic committee nor a written antibiotic policy.
Clinical guidelines, or policies, are defined as 'systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances'. 15 They are considered to be at the cornerstone of efforts to improve antibiotic use by educational means. 16, 17 They are not, however, supported by all practitioners 18 and it has been said that the profession is suffering from guideline overload. Certainly, there are thousands of national and international clinical guidelines available and the burden for clinicians to deliver timely evidence-based healthcare is considerable. 19 In 2002, Brown 15 summarized the principal features of guideline development, including multidisciplinary and expert involvement, based on scientifically robust evidence, that they should not be excessively long (e.g. 20 -25 pages) and should be reviewed at periodic intervals (e.g. at least every 2 years). Our data suggested that accessibility to guidelines was suboptimal; many policy documents were too big to fit into a coat pocket, were not indexed or were not available on the hospital intranet. Clearly there was a wide range in length of policies, with average size being twice as long as recommended in the literature. 15 We found evidence of multidisciplinary involvement in both policies and antibiotic-related committees. There is a general consensus that guidelines need local input to reflect local antibiotic susceptibility patterns. This was found in our survey, with 59% of hospital policies referring to local resistance patterns, although less than half of policies had been updated in the previous 2 years. One-half of all respondents failed to answer the question on timing of policy revision. Many did not reflect recent changes in antibiotic resistance levels, such as increasing methicillin-resistant Staphylococcus aureus (MRSA) rates, although we know from other ARPAC data it was common for local laboratories to publish resistance rates. 10 Many policies recommended first and second choices for empirical therapy and prophylaxis, including advice on dose, duration, oral switch, use of the laboratory for diagnosis and resistance patterns. There was less guidance on severity assessment and side effects, which are crucial areas for improving the quality of antibiotic prescribing. 20 There was also little apparent use of antibiotic cycling, 21 which correctly reflects the lack of good data on the efficacy of this measure. Similarly, there was a lack of data on costs of products within the empiric therapy recommendation section of antibiotic policies. However, from other analyses presented elsewhere, we know that approximately one-third of hospitals had administration cost restrictions at a local or national level. 10 For surgical prophylaxis there was an emphasis on timing of antibiotic administration and the importance of single-dose prophylaxis for most operations because of the dangers of antibiotic resistance. 22 Antibiotic stewardship measures should facilitate change in clinical practice. However, we failed to identify any significant relationship between selected key criteria and total antibiotic consumption. There are many factors that may contribute to this lack of an apparent effect, such as measurement bias, whether we failed to consider the most appropriate 'stewardship' criteria, the use of aggregated antibiotic consumption data or failure to account for potential confounding factors. In particular, it should be highlighted that we looked only at quantitative antibiotic use and not at qualitative reasons for use. Quantitative use was highly variable across the five European regions studied. It is possible that some hospitals may have prescribed low-level use of broad-spectrum antibiotics, whilst other hospitals may have prescribed relatively larger amounts of narrow-spectrum antibiotics, some of which may have been prescribed in combination. Previously, however, we found that hospitals with greater numbers of antibiotics on their formulary were associated with higher antibiotic use, 9 suggesting that the existence of a formulary may reduce quantitative antibiotic use. Although Northern Europe's median total antibiotic use was similar to the value for all participating hospitals, the difference between the minimum and maximum values was much smaller than for any other region. 8, 9 This suggests that hospitals in Northern European had much better control of the quantities of antibiotics used. The penicillins (class J01C) and other b-lactams (class J01D) accounted for the highest proportion of antibiotic use and were explored in more detail. 23 Differences observed in these diverse classes included the fact that Northern Europe used very small quantities of penicillins combined with b-lactamase inhibitors, unlike the other regions which used very high proportions of this subclass, particularly Western and Southern Europe. 23 When class J01D was investigated, Western and Southern Europe used significantly more third-generation cephalosporins and carbapenems than the other regions. Such high usage of broad-spectrum antibiotics may be related to differences either in antibiotics stewardship or in the antibiograms of key pathogens in these regions. 8 Our questionnaire was detailed and many items could have been selected as quality indicators of good practice or stewardship. Given the volume of data, there was a risk of multiple statistical testing, and potential for post hoc data-dredging, hence key indicators were agreed a priori by the Steering Group and a statistical protocol was developed and adhered to. This was a large-scale survey of institutions and we were unable to unravel or explore local circumstances, e.g. whether hospital policies had been adapted for the local setting or reflected regional antimicrobial resistance patterns. Prescribing will depend upon hospital case mix and local experience with pathogens, which will be reflected in recommendations for empirical and definitive therapies.
Other strengths of this pan-European study include the large sample of hospitals, rigorous, planned data collection methods and high-quality data from participating hospitals. We acknowledge that hospitals were self-selecting, thus increasing the risk of response bias, but this makes the paucity of stewardship strategies even more surprising. The cross-sectional design provides a snapshot of practice and it is not possible to attribute cause and effect. For example, interventions such as setting strategic goals and restrictive antibiotic lists may have been established more recently in response to high antibiotic consumption. Consequently, the perception that their existence is associated with high antibiotic consumption in a causative manner may be false. This is a phenomenon called 'reactive practice' and has been described recently by Mears et al. 24 They suggested that apparent relationships between infection control interventions and higher infection rates were counterintuitive and an example of reactive practice. Also, other factors, such as wider cultural determinants, which we did not measure, are important to consider when determining antibiotic consumption. Harbarth and Monnet 25 have highlighted five groups of determinants of the observed differences in the use of antimicrobial agents including pathogen characteristics, physicians' antibiotic prescribing practices, antibiotic demand/patient characteristics, cultural/ socioeconomic factors and the healthcare/legal environment. Moreover, it is also important to consider the wider impact of antibiotic consumption on trends of antimicrobial resistance, mortality, morbidity and other patient-related outcomes.
Clearly, there is a considerable way to go with antibiotic stewardship before we can achieve high standards throughout hospitals in Europe. Other recently established antibiotic projects, such as Antibiotic Stewardship International, 4 are commendable and will provide valuable process and outcome data for the selected European hospitals participating in intensive stewardship programmes. 26 In conclusion, our European survey found considerable room for improvement in hospital antibiotic stewardship.
